Next Article in Journal
Oxidation Stress-Mediated MAPK Signaling Pathway Activation Induces Neuronal Loss in the CA1 and CA3 Regions of the Hippocampus of Mice Following Chronic Cold Exposure
Previous Article in Journal
Mid-Frontal Theta Modulates Response Inhibition and Decision Making Processes in Emotional Contexts
Open AccessArticle

Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study

1
Movement Disorders Unit, Clínica Universidad de Navarra (CUN), 31008 Pamplona, Spain
2
IdiSNA (Navarra Institute for Health Research), 31008 Pamplona, Spain
3
Movement Disorders Unit, Hospital Universitario Insular de Gran Canaria, 35016 Las Palmas de Gran Canaria (HUIGC), Spain
4
Movement Disorders Unit, Hospital de la Santa Creu i Sant Pau (HSCSP), 08041 Barcelona, Spain
5
Movement Disorders Unit, Hospital Universitario de Badajoz, 06080 Badajoz, Spain
*
Author to whom correspondence should be addressed.
Brain Sci. 2019, 9(10), 272; https://doi.org/10.3390/brainsci9100272
Received: 28 August 2019 / Revised: 29 September 2019 / Accepted: 9 October 2019 / Published: 11 October 2019
(This article belongs to the Special Issue Progression of Cognitive Decline in Older Adults with Parkinson’s)
Background: Safinamide is an approved drug for the treatment of motor fluctuations of Parkinson’s Disease (PD) patients with a potential benefit on non-motor symptoms (NMS). Methods: A retrospective multicenter cohort study was conducted, in which the clinical effect of safinamide on both motor and NMS was assessed by the Clinical Global Impression of Change scale. Furthermore, we assessed the appearance of adverse events (AEs) and its effect on dyskinesia, that were also recorded in non-fluctuating PD patients and in those previously treated with rasagiline. Results: We included 213 PD patients who received safinamide in addition to their regular levodopa therapy. Thirty-five withdrew prematurely from safinamide, mainly because of AEs. Out of 178, clinical improvement on motor and NMS was found in 76.4% and 26.2%, respectively. A total of 44 reported AEs of mild intensity. We did not find a difference concerning the clinical benefit or AEs when comparing either patients who had or had not been taking Monoamine Oxidase B Inhibitor (MAOB-I) previously or between patients with and without motor complications. Conclusions: Safinamide is an effective and safe add-on to levodopa drug for PD patients. Moreover, safinamide could elicit an additional clinical improvement in PD patients previously treated with other MAOB-I and in non- fluctuating patients with suboptimal motor control. View Full-Text
Keywords: Parkinson’s Disease; Safinamide; Adverse drug event; Dyskinesia; Drug-Induced; Motor complications Parkinson’s Disease; Safinamide; Adverse drug event; Dyskinesia; Drug-Induced; Motor complications
MDPI and ACS Style

Martí-Andrés, G.; Jiménez-Bolaños, R.; Arbelo-González, J.M.; Pagonabarraga, J.; Duran-Herrera, C.; Valenti-Azcarate, R.; Luquin, M.R. Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study. Brain Sci. 2019, 9, 272.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop